Covered recipient · General Payments record
MARIA BRAUN
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,611.11
- Reported across 87 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $308.07 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $176.38 | 10 |
| Novo Nordisk AS | $50.28 | 2 |
| Esperion Therapeutics, Inc. | $20.96 | 1 |
| Lilly USA, LLC | $19.86 | 1 |
| Acerta Pharma LLC | $13.81 | 1 |
| PFIZER INC. | $13.59 | 1 |
| GlaxoSmithKline, LLC. | $13.19 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $21.58 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103363865 | CMS |
| ABBVIE INC. | $18.81 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103363867 | CMS |
| ABBVIE INC. | $22.83 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103363869 | CMS |
| ABBVIE INC. | $23.56 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103363871 | CMS |
| ABBVIE INC. | $24.78 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103363873 | CMS |
| ABBVIE INC. | $5.36 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103363875 | CMS |
| ABBVIE INC. | $6.55 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103363877 | CMS |
| ABBVIE INC. | $19.40 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103363879 | CMS |
| ABBVIE INC. | $12.34 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103363881 | CMS |
| ABBVIE INC. | $21.17 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103363883 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.81 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105679563 | CMS |
| Esperion Therapeutics, Inc. | $20.96 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129428998 | CMS |
| GlaxoSmithKline, LLC. | $13.19 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116292035 | CMS |
| Lilly USA, LLC | $19.86 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135165745 | CMS |
| Novo Nordisk Inc | $27.32 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097443261 | CMS |
| Novo Nordisk Inc | $22.96 | 12/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096715317 | CMS |
| PFIZER INC. | $13.59 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131754206 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.